Back

Title
  • en Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment
Creator
Accessrights open access
Rights
  • en This is the peer reviewed version of the following article: Asano, T., Hirano, S., Nakamura, T., Okamura, K., Tsuchikawa, T., Noji, T., Nakanishi, Y., Tanaka, K. and Shichinohe, T. (2018), Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment. J Hepatobiliary Pancreat Sci, 25: 342-350., which has been published in final form at https://doi.org/10.1002/jhbp.565. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Subject
  • Other en Conversion surgery
  • Other en Multidisciplinary treatment
  • Other en Prognosis
  • Other en Survival analysis
  • Other en Unresectable pancreatic cancer
  • NDC 490
Description
  • Abstract en Background: Conversion surgery (CS) is expected as a new therapeutic strategy for patients with unresectable pancreatic cancer (UR-PC). We analyzed outcomes of CS for patients with UR-PC and evaluated the survival benefit of CS. Methods: Thirty-four patients diagnosed with UR-PC according to the National Comprehensive Cancer Network guideline underwent CS in our hospital. Resectability was considered by multimodal images in patients who underwent nonsurgical treatment (NST) for more than 6 months. CS was performed only in patients who were judged to be able to undergo R0 resection. Results: Twenty-six patients had locally advanced PC, and eight had distant metastases. The median duration of NST was 9 (range 5-44) months. R0 resection was achieved in 30 patients (88.2%). Six patients (17.6%) showed Evans grade ≥III. Three- and 5-year overall survival (OS) rates from initial treatment were 74% and 56.9%, respectively, with median survival time (MST) of 5.3 years. The actual 5-year OS rate in 19 patients was 47.4% with an MST of 4.0 years. Patients with Evans grade ≥III had a better prognosis than those with Evans grade <III (P = 0.0092, log-rank test). Conclusions: Conversion surgery might have survival benefits to patients with UR-PC who responded favorably to NST.
Publisher en John Wiley & Sons
Date
    Issued2018-07
Language
  • eng
Resource Type journal article
Version Type AM
Identifier HDL http://hdl.handle.net/2115/74831
Relation
  • isVersionOf DOI https://doi.org/10.1002/jhbp.565
  • PMID 29797499
Journal
    • PISSN 1868-6974
      • en Journal of hepato-biliary-pancreatic sciences
      • Volume Number25 Issue Number7 Page Start342 Page End350
File
Oaidate 2023-07-26